Noncoding RNAs and DNA methylation as epigenetic modulators of breast cancer: mechanisms and clinical perspectives in the Iranian population, a systematic review Authors: Zeynab Mashayekh, Rasool Fatehi Fard, Sadeq Vallian Published: 2025 ABSTRACT ObjectiveNoncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), play critical epigenetic roles in regulating gene expression and cancer development. Dysregulation of these molecules is closely associated with breast cancer initiation, progression, metastasis, and therapeutic resistance. Another major epigenetic mechanism, DNA methylation, also contributes to cancer susceptibility.MethodsFollowing PRISMA guidelines, a systematic search was conducted in PubMed, Scopus, IranMedex, and Magiran for studies published between 2019 and 2024. Eligible studies investigated the roles of ncRNAs and/or DNA methylation in breast cancer. Data extraction and study selection were performed according to predefined inclusion criteria.ResultsThe study identified several dysregulated ncRNAs, including miR-155, miR-605, ZEB2-AS1, MALAT1, AK058003, SGO-AS1, and circ_0005046, that regulate key cellular processes including apoptosis, proliferation, invasion, and therapy resistance. Additionally, aberrant DNA methylation of genes such as PGR, ISL1, and MGMT was associated with altered gene expression and an increased risk of breast cancer.ConclusionBoth ncRNAs and DNA methylation demonstrate strong potential as diagnostic and prognostic biomarkers with clinical relevance in breast cancer. To our knowledge, this is the first systematic review to integrate findings from both international and Iranian studies, providing a comprehensive overview of epigenetic regulation in breast cancer.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-025-15430-z. Introduction Breast cancer remains one of the most significant global health challenges, accounting for approximately 670,000 deaths worldwide in 2022. It is the most frequently diagnosed cancer among women and the second most common cancer overall [1]. In the same year, the Global Cancer Observatory (GLOBOCAN) reported a breast cancer mortality rate of about 11.0 per 100,000 in Iran, a figure disproportionately high considering the country’s comparatively lower incidence relative to high-income nations [1]. This excess mortality is largely attributed to delayed diagnosis, with many patients presenting at advanced stages when treatment is less effective [2]. These observations underscore the urgent need for improved strategies in early detection and effective treatment. Recent advances in the molecular understanding of breast cancer suggest that genetic factors, particularly those governing epigenetic modifications, play a critical role in disease initiation and progression [3]. Recent studies have further elucidated the molecular heterogeneity of breast cancer, emphasizing the role of genomic and transcriptomic alterations in tumor evolution and clinical behaviour [4]. With the development and increasing accessibility of molecular techniques, Iranian researchers have devoted considerable attention over the past decade to investigating and characterizing epigenetic alterations in breast cancer. Epigenetic modifications regulate gene expression and maintain cellular identity without altering the DNA sequence itself [5]. These include DNA methylation, histone modifications, and noncoding RNA-mediated gene silencing. Importantly, they can be shaped by environmental exposures and lifestyle factors, thereby exerting profound effects on health and disease susceptibility [5]. The investigation of epigenetic markers across populations has become a pivotal area of research, offering valuable insights into the mechanisms of tumorigenesis, including breast cancer [6]. The present review provides a comprehensive synthesis of recent findings on epigenetic modifiers in breast cancer, with a particular emphasis on research conducted in Iran alongside global evidence (Fig. 1). We summarize methodologies employed for the identification and analysis of these markers, drawing on both population-based studies and experimental work using cell lines. By considering the combined influence of genetic background, environmental exposures, and lifestyle factors on epigenetic regulation, this review aims to clarify their contribution to breast cancer susceptibility and health disparities. Finally, we introduce a list of genes implicated in epigenetic alterations that hold promise as molecular markers for breast cancer diagnosis in the Iranian population. Fig. 1Epigenetic regulation of breast cancer by epigenetic modifiers. Noncoding RNAs (miRNAs, lncRNAs, circRNAs) and DNA methylation regulate key hallmarks of breast cancer, driving tumor progression and therapy resistance. Their integration as biomarkers offers promising avenues for early detection, prognosis, and personalized epigenetically targeted therapies Epigenetic regulation of breast cancer by epigenetic modifiers. Noncoding RNAs (miRNAs, lncRNAs, circRNAs) and DNA methylation regulate key hallmarks of breast cancer, driving tumor progression and therapy resistance. Their integration as biomarkers offers promising avenues for early detection, prognosis, and personalized epigenetically targeted therapies Materials and methods Information sources and search strategy A systematic literature search was conducted in both international and Iranian databases, including PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), Scopus (https://www.scopus.com/), IranMedex (https://www.iranmedex.com/), and Magiran (https://www.magiran.com/). The search covered studies published from January 2019 to December 2024. The following keywords and Boolean combinations were used: ‘noncoding RNA’, ‘circRNA’, ‘miRNA’, ‘lncRNA’, ‘methylation’, ‘phosphorylation’, ‘epigenetic’, ‘diagnosis’, and ‘breast cancer’. The search strategy was tailored for each database. Additionally, reference lists of all included studies and relevant reviews were manually screened to ensure completeness. Databases were selected based on their coverage of both international and regional biomedical literature related to the Iranian population. PubMed and Scopus were included for their comprehensive indexing of global biomedical studies, while IranMedex and Magiran were chosen to capture Persian-language publications. Embase and Ovid Medline were not included because preliminary scoping searches indicated the presence of substantial overlap with PubMed results. The selected combination of databases was therefore considered sufficient to ensure comprehensive retrieval of relevant Iranian studies. The review process followed the 2020 guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Eligibility criteria Inclusion criteria Studies investigating the role of epigenetic modifiers, including noncoding RNAs, circRNAs, miRNAs, lncRNAs, DNA methylation, histone modifications, or phosphorylation in breast cancer within the Iranian population were considered. These studies were based on in vitro experiments, cell lines, or tissue samples related to breast cancer. They were published in English or Persian and appeared in journals with an impact factor ≤ 2.5. Exclusion criteria Reviews, case reports, conference abstracts, purely in silico studies and studies without primary experimental data were ruled out. Also, articles not specific to the Iranian population were excluded. Screening process and study selection All retrieved records were imported into a reference manager, and duplicates were removed. The First reviewer screened titles and abstracts for eligibility. Full texts of potentially relevant articles were obtained and evaluated against the inclusion criteria. Discrepancies were resolved by discussion or by consulting a third reviewer. Data extraction The first author performed data extraction using a standardized approach. From each eligible study, information was collected on publication year, study design, type of epigenetic modifier investigated, sample source (cell line or tissue), main outcomes, and the most frequently reported genes or pathways. The extracted data were organized and managed in Microsoft Excel spreadsheets to facilitate comparison and synthesis. Risk of bias/quality assessment and data synthesis A narrative synthesis was undertaken. Findings were grouped according to the type of epigenetic modification and its functional role in breast cancer. To provide context, results were compared with studies reporting similar markers in non-Iranian populations. Reporting This review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A PRISMA flow diagram outlining the study selection process is presented in the Results section. Results Study selection A total of 269 records on diagnostic biomarkers in Iranian breast cancer patients (2019–2024) were identified through database searches. After screening the titles and abstracts, 196 records were excluded for irrelevance, non-diagnostic focus, or non-Iranian samples. 73 full-text articles were assessed for eligibility and included in the qualitative synthesis (Fig. 2), comprising 33 miRNA, 20 lncRNA, 8 circulating circRNA, 8 circRNA, and 4 DNA methylation studies. Excluded studies were reviews, case reports, conference abstracts, purely in silico, lacked primary data, or were not specific to the Iranian population. Fig. 2PRISMA flow diagram of study selection for diagnostic biomarker studies in Iranian breast cancer patients (2019–2024). A total of 1,313 records were identified through database searches, and 25,253 through additional searches. After removing duplicates and screening titles and abstracts, 67 full-text articles were assessed for eligibility. Manual reference checking yielded six additional eligible studies, resulting in a final inclusion of 73 studies for qualitative synthesis PRISMA flow diagram of study selection for diagnostic biomarker studies in Iranian breast cancer patients (2019–2024). A total of 1,313 records were identified through database searches, and 25,253 through additional searches. After removing duplicates and screening titles and abstracts, 67 full-text articles were assessed for eligibility. Manual reference checking yielded six additional eligible studies, resulting in a final inclusion of 73 studies for qualitative synthesis Small noncoding RNAs Noncoding RNAs (ncRNAs) are broadly classified into two categories: short and long. Among the short ncRNAs, microRNAs (miRNAs) are small, noncoding RNA molecules 18–24 nucleotides in length that regulate gene expression at the post-transcriptional and translational levels [7]. Most miRNAs bind to the 3′ untranslated region (3′ UTR) of target messenger RNAs (mRNAs), where they repress translation or promote mRNA degradation [3]. Dysregulation of miRNAs has been reported in multiple cancers, including breast cancer. For example, aberrant expression of miRNAs and long ncRNAs involved in endoplasmic reticulum stress has been shown to affect cancer cell survival and promote cell death [8]. Similarly, studies on the Notch signaling pathway revealed that deregulation of miRNAs, lncRNAs, and circRNAs contributes to breast cancer development by modulating this pathway [9]. Environmental exposures such as endocrine disruptors, heavy metals, and air pollutants have also been implicated in shifting miRNA expression patterns toward promoting breast cancer progression [10]. MiRNAs play essential roles in regulating apoptosis, and their dysregulation influences cell growth, differentiation, and death, ultimately increasing the risk of tumor progression [11]. Furthermore, ncRNAs have been shown to participate in the conversion of normal fibroblasts into cancer-associated fibroblasts (CAFs), a process that promotes tumor development [12]. Several studies have also highlighted the diagnostic potential of miRNAs, particularly in aggressive subtypes such as triple-negative breast cancer [13]. In total, 37 studies on miRNAs were identified, of which 33 met our keyword-based inclusion criteria. For instance, overexpression of miR-216b-5p was shown to inhibit cell proliferation by targeting the 3′ UTR of HDAC8 mRNA, thereby suppressing tumor growth [14]. Similarly, cell line analysis for miR-29c identified it as a tumor suppressor, with subtype-specific expression patterns [15]. The lncRNA C1orf132 (MIR29B2CHG), a host gene for miR-29b, is downregulated in triple-negative breast cancer (TNBC), leading to enhanced cell migration, while its restoration inhibits progression [16]. MiR-34a, miR-9, miR-192, miR-200c, miR-143-3p and miR-361-5p A review revealed the deregulation of miR-29b in different subtypes of breast cancer [17]. In the Iranian cohort, downregulation of miR-34a and miR-9 has been observed in patients with advanced-stage breast cancer compared with early stages [18]. Similarly, decreased expression of miR-9 and miR-192 has been reported in tumors relative to adjacent normal tissue [19]. Downregulation of miR-34a and miR-200c in tumor tissues has also been linked with reduced apoptosis and impaired cell cycle arrest, whereas restoring their expression suppressed tumor growth in xenograft models [20]. Conversely, miR-141, another member of the miR-200 family, was upregulated in tumor tissue samples, correlating with increased expression of its target genes E2F, CDK3, and KAT2B [21]. Downregulation of miR-143-3p has been associated with elevated levels of the lncRNA MALAT1, suggesting reciprocal regulation in breast cancer. Additionally, the RALGAPA2 rs3827693 G allele has been reported to reduce the risk of breast cancer [22]. Low expression of miR-361-5p correlated with high levels of the oncogene WT1, which enhances proliferation, metastasis, and resistance to apoptosis [23]. MiR-10b, miR-21, miR-451, miR-22, miR-125 and miR-181 Breast cancer stem cells (BCSCs) exhibit self-renewal, differentiation, migration, metastasis, and therapy resistance, making them highly aggressive [24]. Dysregulation of multiple signaling pathways, including MAPK, PI3K/Akt/NFκB, TGF-β, Wnt/β-catenin, Notch, Hedgehog, and Hippo, facilitates the transition of breast cancer cells into BCSCs. Several miRNAs, including miR-10b, miR-21, miR-22, miR-125, and miR-181, are upregulated in BCSCs and contribute to their stemness phenotypes [25]. Targeting these miRNAs may therefore reduce therapy resistance. On the other hand, another study showed that plasma levels of miR-21 and miR-451 were found to be altered in primary and recurrent breast cancer patients, suggesting their potential as non-invasive biomarkers for disease detection and monitoring [26]. Additionally, miR-125a-5p was found to be downregulated in breast cancer tissues, resulting in STAT3 upregulation; its reduced expression, linked to promoter hypermethylation, supports a tumor suppressor role [27]. MiR-127-3p, miR-133a-3p, miR-199b-5p, and miR-342-5p miR-155-5p In silico studies identified several miRNAs that can distinguish tumor from non-tumor samples in breast cancer, including significant downregulation of miR-127-3p, miR-133a-3p, miR-199b-5p, and miR-342-5p, along with upregulation of miR-155-5p [28]. Iranian researchers also developed a signal-off diagnostic method to evaluate the utility of miR-155 and miR-21 for early breast cancer detection [29, 30]. Elevated levels of hsa-miR-25-3p, −29a-5p, −105-3p, and − 181b1-5p, alongside reduced expression of hsa-miR-335-5p and − 339-5p, were reported in an Iranian cohort [31]. Other studies highlighted the downregulation of miR-152-3p following chemotherapy [32], decreased expression of miR-140, and increased expression of miR-196a in tumor tissues, all of which were associated with lymph node metastasis, tumor stage, and higher tumor grade [33]. MiR-181a and miR-30d MiR-181a and miR-30d regulate the PI3K/Akt pathway [34]. In an Iranian study of tissue samples, miR-181a was significantly upregulated and miR-30d downregulated in breast tumors compared with adjacent normal tissue [35]. Elevated levels of miR-181a-3p were associated with more advanced disease [36]. Expression levels of miR-133a, miR-637, and miR-944 were investigated in breast cancer patients and found to be associated with PI3K/AKT signaling, suggesting their potential roles in tumor progression and as therapeutic targets [37]. A case–control study on serum samples further identified deregulation of the Xq27.3 miRNA cluster (miR-506, miR-507, miR-508, miR-513, miR-891, miR-892a, and miR-892b) in patient serum, suggesting their potential as non-invasive diagnostic markers [38]. MiR-93-3p MiR-93 regulates nuclear factor of activated T-cells cytoplasmic 1 and 3 (NFATc1, NFATc3). Study on blood samples of Iranian patients, miR-93-3p expression was significantly higher compared to healthy women, while NFATc1 and NFATc3 expression in PBMCs was reduced [39]. MiR-203a-3p Based on cell line investigation, miR-203a-3p suppresses cell cycle regulators such as Cyclin D1 and c-Myc, thereby inhibiting PI3K/Akt and Wnt signaling. Overexpression of miR-203a-3p induces cell cycle arrest, reduces proliferation and migration, and promotes apoptosis of breast cancer cells [40]. MiR-561-3p A cell line study illustrated that downregulation of miR-561-3p has been associated with increased expression of ZEB1, HIF1A, and MYC, contributing to tumor progression. Overexpression of miR-561-3p suppressed PD-L1 expression at both mRNA and protein levels, reduced proliferation, and induced apoptosis and cell cycle arrest through inhibition of these oncogenes [41]. miR-660-5p and miR-210-3p Circulating levels of miR-660-5p and miR-210-3p were found to be altered in breast cancer patients, indicating their potential as non-invasive biomarkers for disease detection and monitoring [42]. MiR-605 rs2043556 A case-control study of 162 patients and 180 controls demonstrated that the rs2043556 polymorphism in miR-605 is associated with an increased risk of breast cancer in Iranian women [43]. On the other hand, blood sample studies showed that polymorphisms rs2682818 in miR-618 and rs2043556 in miR-605 have been validated as genetic variants associated with increased susceptibility to breast cancer, highlighting their potential as diagnostic genetic markers [44]. Table 1 represents the most impactful miRNAs mentioned in this study, summarizing their expression pattern, functional role, and key targets/pathways. Table 1The most impactful miRNAs mentioned in this studymiRNAExpression in BCFunctional RoleKey Pathway/Target(s)Ref(s)miR-34aDown in tumors, restoration induces apoptosis & G1 arrestTumor suppressor; inhibits growthCell-cycle/apoptosis regulators[18, 20]miR-9Down in tumorsTumor suppressor; BC progressionMultiple pathways[18, 19]miR-200cDown in tumors, restoration suppresses growthTumor suppressor; EMT restraintEMT/cell-cycle control[20]miR-141,miR-590-5p,miR-23b-3p,miR-191-5PUp in tumorsOncogenic; promotes proliferationE2F, CDK3, KAT2B[21]miR-21Up (notably in BCSCs), diagnostic candidateOncogenic; therapy resistancePI3K/Akt/NFκB, others[26, 29, 30]miR-125a-5pDown in tumorsTumor suppressorSTAT3 (up when miR-125a-5p reduced)[27, 45]miR-181aUp in tumors, associated with progressionOncogenic; drives progressionPI3K/Akt[35, 36]miR-25-3p,miR-29a-5p,miR-105-3p,miR-181b1-5pUp in associated progressionOncogenic: drives progressionMultiple[31]miR-335-5p,miR-339-5pDown in the associated progressionTumor suppressors; Drive progressionMultiple[31]miR-30dDown in tumorsTumor suppressorPI3K/Akt[35]miR-92a-3pDownTumor suppressor; EMT and invasionLow GATA3, progression[46, 47]miR-1245b-5pDownTumor suppressor; EMT and invasionLow GATA3, progression[47]miR-93-3pUp in patients’ blood, NFATc1/3 reducedOncogenic/immune modulationNFATc1, NFATc3[39]miR-203a-3pFunctional suppression of malignancy when overexpressedTumor suppressor; apoptosis & cell-cycle arrestPI3K/Akt, Wnt (Cyclin D1, c-Myc)[40]miR-561-3pDown in tumorsTumor suppressor; reduces PD-L1 and proliferationZEB1, HIF1A, MYC; PD-L1[41, 48]miR-29bSubtype-specific; suppressiveTumor suppressorMIR29B2CHG/miR-29 axis[31]miR-216b-5pOverexpression; inhibits proliferationTumor suppressorHDAC8 (3′-UTR binding)[14]miR-143-5pDown in cancer tissuesTumor suppressorTargeting Oncogenic HMGA2[49]miR-143-3pDown in patientsTumor suppressor; inversely related to MALAT1MALAT1 axis[22]miR-361-5pLow in tumorsTumor suppressor; anti-proliferative/anti-metastaticWT1 (↑ when miR-361-5p low)[23]miR-155-5pUp in tumors; diagnostic candidateOncogenic; inflammation/immune-linkedMultiple[29, 50, 51]miR-210-3pmiR-660-5pUp in tumors;Diagnostic accuracyOncogenic; circulating miRNAsCancer-relevant processes[42]miR-637Down in tumors;Diagnostic & prognostic candidateTumor suppressor; Therapeutic targetPI3K-AKT pathway; HER2 receptor[37]Abbreviations: BC Breast Cancer, EMT Epithelial-Mesenchymal Transition, Down Downregulated, Up Upregulated, BCSC Breast Cancer Stem Cells Table 1The most impactful miRNAs mentioned in this studymiRNAExpression in BCFunctional RoleKey Pathway/Target(s)Ref(s)miR-34aDown in tumors, restoration induces apoptosis & G1 arrestTumor suppressor; inhibits growthCell-cycle/apoptosis regulators[18, 20]miR-9Down in tumorsTumor suppressor; BC progressionMultiple pathways[18, 19]miR-200cDown in tumors, restoration suppresses growthTumor suppressor; EMT restraintEMT/cell-cycle control[20]miR-141,miR-590-5p,miR-23b-3p,miR-191-5PUp in tumorsOncogenic; promotes proliferationE2F, CDK3, KAT2B[21]miR-21Up (notably in BCSCs), diagnostic candidateOncogenic; therapy resistancePI3K/Akt/NFκB, others[26, 29, 30]miR-125a-5pDown in tumorsTumor suppressorSTAT3 (up when miR-125a-5p reduced)[27, 45]miR-181aUp in tumors, associated with progressionOncogenic; drives progressionPI3K/Akt[35, 36]miR-25-3p,miR-29a-5p,miR-105-3p,miR-181b1-5pUp in associated progressionOncogenic: drives progressionMultiple[31]miR-335-5p,miR-339-5pDown in the associated progressionTumor suppressors; Drive progressionMultiple[31]miR-30dDown in tumorsTumor suppressorPI3K/Akt[35]miR-92a-3pDownTumor suppressor; EMT and invasionLow GATA3, progression[46, 47]miR-1245b-5pDownTumor suppressor; EMT and invasionLow GATA3, progression[47]miR-93-3pUp in patients’ blood, NFATc1/3 reducedOncogenic/immune modulationNFATc1, NFATc3[39]miR-203a-3pFunctional suppression of malignancy when overexpressedTumor suppressor; apoptosis & cell-cycle arrestPI3K/Akt, Wnt (Cyclin D1, c-Myc)[40]miR-561-3pDown in tumorsTumor suppressor; reduces PD-L1 and proliferationZEB1, HIF1A, MYC; PD-L1[41, 48]miR-29bSubtype-specific; suppressiveTumor suppressorMIR29B2CHG/miR-29 axis[31]miR-216b-5pOverexpression; inhibits proliferationTumor suppressorHDAC8 (3′-UTR binding)[14]miR-143-5pDown in cancer tissuesTumor suppressorTargeting Oncogenic HMGA2[49]miR-143-3pDown in patientsTumor suppressor; inversely related to MALAT1MALAT1 axis[22]miR-361-5pLow in tumorsTumor suppressor; anti-proliferative/anti-metastaticWT1 (↑ when miR-361-5p low)[23]miR-155-5pUp in tumors; diagnostic candidateOncogenic; inflammation/immune-linkedMultiple[29, 50, 51]miR-210-3pmiR-660-5pUp in tumors;Diagnostic accuracyOncogenic; circulating miRNAsCancer-relevant processes[42]miR-637Down in tumors;Diagnostic & prognostic candidateTumor suppressor; Therapeutic targetPI3K-AKT pathway; HER2 receptor[37]Abbreviations: BC Breast Cancer, EMT Epithelial-Mesenchymal Transition, Down Downregulated, Up Upregulated, BCSC Breast Cancer Stem Cells The most impactful miRNAs mentioned in this study miR-141, miR-590-5p, miR-23b-3p, miR-191-5P miR-25-3p, miR-29a-5p, miR-105-3p, miR-181b1-5p miR-335-5p, miR-339-5p miR-210-3p miR-660-5p Up in tumors; Diagnostic accuracy Down in tumors; Diagnostic & prognostic candidate Abbreviations: BC Breast Cancer, EMT Epithelial-Mesenchymal Transition, Down Downregulated, Up Upregulated, BCSC Breast Cancer Stem Cells Long noncoding RNAs Long noncoding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides that lack protein-coding potential [52]. They have been implicated in diverse biological processes, including cell proliferation, differentiation, and apoptosis, as well as in the initiation and progression of various diseases, particularly cancer [53]. Through our systematic search, 117 Iranian studies on lncRNAs were retrieved, and after screening for relevance based on predefined keywords, 20 studies were included in the qualitative synthesis, highlighting key findings in the field. DSCAM-AS1 DSCAM-AS1 is an oncogenic lncRNA that contributes to cancer progression. Several Iranian studies have reported altered expression of this transcript in breast cancer. A review highlighted its consistent upregulation across multiple cancers, including breast cancer [54]. Specifically, Iranian cohorts have demonstrated increased expression of DSCAM-AS1 in tumor tissues, adjacent noncancerous tissues [55], and blood samples [56]. MALAT1 and TOP2A Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been strongly linked to tumor metastasis in multiple cancers, including breast cancer. In Iranian patients and cell line studies, MALAT1 expression was consistently elevated compared with normal controls. In one study, MALAT1 upregulation was associated with increased expression of its downstream effector TOP2A, while miR-561-3p was concurrently suppressed. Mechanistically, MALAT1 acted as a competing endogenous RNA (ceRNA), sequestering miR-561-3p and thereby promoting proliferation and metastasis in MCF-7 and MDA-MB-231 cells [48]. Another investigation confirmed MALAT1 overexpression in breast tumor tissues of Iranian women [22]. Moreover, ceRNA network analysis of microarray data further supported differential MALAT1 expression in breast cancer [57]. LncUSMycN LncUSMycN, which was originally described as an oncogene in neuroblastoma [58], has also been implicated in breast cancer. Studies in Iranian breast cancer cell models (ZR-75-1, MCF7, MDA-MB-231) demonstrated that LncUSMycN knockdown suppressed migration and induced apoptosis, supporting its oncogenic role [59]. Shugoshin-like protein 1- antisense 1 (SGO1-AS1) Shugoshin-like protein 1 antisense RNA 1 (SGO1-AS1) is involved in proper mitotic regulation and has been suggested to suppress invasion and metastasis in several cancers, including gastric cancer [60]. For the first time, Iranian researchers reported significant downregulation of SGO1-AS1 in breast tumor tissues compared with adjacent normal tissues [61]. Zinc finger E-box binding homeobox 2-antisense RNA1 (ZEB2-AS1) Zinc finger E-box binding homeobox 2 antisense RNA 1 (ZEB2-AS1, also known as ZEB2NAT) is transcribed under the regulation of the TGF-β pathway and has been linked to tumor cell growth and epithelial–mesenchymal transition (EMT) [62]. Multiple studies in Iranian breast cancer cohorts have documented its oncogenic role. One review confirmed its relevance in cancer progression [63]. In tissue-based studies, ZEB2-AS1 expression was significantly upregulated in tumors compared to matched adjacent tissues [64, 65]. Combined in silico and in vitro analyses further revealed its correlation with EMT markers in ductal and lobular breast carcinomas in Iranian women [66]. Adriamycin resistance-related (ARA) Adriamycin resistance-related (ARA) is an oncogene that acts as a cancer promoter via multiple pathways. It was found that ARA was significantly upregulated in breast cancer tissues compared with paired non-tumor samples, as supported by ROC curve analysis, indicating its potential as a novel diagnostic biomarker [67]. Additionally, ARA and ZEB2NAT lncRNAs were significantly upregulated in breast cancer tissues compared with adjacent normal tissues, with their expression correlating with tumor grade, stage, and lymph node metastasis, indicating potential diagnostic and prognostic value [64]. HOTAIR Homeobox transcript antisense intergenic RNA (HOTAIR) is a well-established oncogenic lncRNA that promotes metastasis. Iranian tissue studies confirmed significant upregulation of HOTAIR in breast tumor tissues relative to adjacent controls [68]. lnc-MICAL3-2 (AC016027.1), LINC01063, LINC02381, lnc-DDX31 (AL445645.1), ENST0000615051 and Lnc-TRIM43B-1 Several immune-related lncRNAs have been investigated in Iranian breast cancer patients. An in silico and in vitro study showed that LINC02381 was downregulated in breast tumor tissues and in MCF7 and SKBR3 cell lines [69]. In a larger cohort of 69 tumor tissues, multiple lncRNAs, including lnc-MICAL3-2 (AC016027.1), LINC01063, LINC02381, lnc-DDX31 (AL445645.1), ENST0000615051, and Lnc-TRIM43B-1, were significantly downregulated in tumors compared with control tissues. Among these, Lnc-TRIM43B-1 showed the strongest discriminatory power between tumor and nontumor samples [70]. Furthermore, dysregulation of lncRNA-autophagy-related gene networks has been implicated in breast cancer. For the first time, a study on tumor tissues of Iranian patients, PLBD1-AS1, RAB11B-AS1, and HERPUD2-AS1, was reported as upregulated in tumor tissues compared with controls [71]. CTBP1-AS1 and NALT1 In a case–control study of 100 TNBC tumor tissues, NALT1 and CTBP1-AS1 lncRNAs were significantly upregulated in tumor tissues compared with adjacent non-tumor tissues. A positive correlation was observed between their expression levels [72]. CTBP1-AS2 and SPRY4-IT1 Further evidence from Iranian cohorts on tissue samples demonstrated that CTBP1-AS2 and SPRY4-IT1 were significantly upregulated in breast tumors compared with adjacent noncancerous tissues [73]. In a tumor tissue study, the expression levels of LINC00511, LINC01028, and NME1 in breast cancer tissues from the Isfahan population were studied using both bioinformatics and experimental analyses. LINC00511 and LINC01028 The study revealed that LINC00511 and LINC01028 were dysregulated, leading to the disruption of apoptosis pathways and the potential promotion of breast cancer progression. These findings underscore the diagnostic and mechanistic significance of these lncRNAs as biomarkers of apoptosis in breast cancer [74]. LINC00961 LINC00961 was identified as a dysregulated lncRNA in luminal breast cancer, with case–control and systems biology analyses supporting its potential involvement in tumor biology and its promise as a diagnostic biomarker [75]. B4GALT1-AS1 In a tumor tissue study, B4GALT1-AS1 lncRNA was significantly downregulated in tumors compared with adjacent non-tumor tissues. Its reduced expression was associated with tumor development and progression, suggesting that B4GALT1-AS1 may serve as a potential diagnostic and prognostic biomarker in breast cancer [76]. TUG1 In a study on breast tissue samples, expression profiling of five lncRNAs (FAS-AS1, TUG1, OIP5-AS1, NEAT1, HULC) in breast tumors versus adjacent noncancerous tissues revealed significant dysregulation, with TUG1 being downregulated. Expression patterns were associated with reproductive factors (menarche age, breastfeeding duration) and mitotic rate [77]. PNKY In a study on tissue samples and cell lines of breast cancer, the long non-coding RNA PNKY was found to be significantly upregulated in breast cancer tissues and cell lines. Functional assays indicated that its overexpression promotes cell proliferation, migration, and epithelial–mesenchymal transition (EMT), suggesting a tumor-promoting role. These findings support lncRNA PNKY as a potential oncogenic biomarker involved in breast cancer progression [78]. GAS6-AS1 In a study on tissue specimens, GAS6 was significantly upregulated while its antisense RNA GAS6-AS1 was downregulated in breast cancer, with GAS6-AS1 expression correlating with progesterone receptor status, suggesting distinct roles in tumor progression [79]. Table 2 represents the major lncRNAs implicated in breast cancer with Iranian evidence.Table 2Major LncRNAs implicated in breast cancer (with Iranian evidence)lncRNAExpression in BCFunctional RoleMechanism/PathwayRef(s)DSCAM-AS1Upregulated (tumor tissues, adjacent tissues, blood)OncogenicPromotes cancer progression[55, 56]MALAT1Upregulated (tumor tissues, cell lines)Oncogenic; promotes proliferation & metastasisceRNA with miR-561-3p, ↑TOP2A[22, 48, 80]LncUSMycNUpregulatedOncogenicSupports proliferation, migration; knockdown induces apoptosis[59]SGO1-AS1Downregulated (tumors vs. adjacent tissues)Tumor suppressorMitotic regulation; loss may promote invasion/metastasis[61]ZEB2-AS1(ZEB2NAT)UpregulatedOncogenic; EMT regulatorTGF-β–induced; correlates with EMT markers[63–67]HOTAIRUpregulated (tumor vs. normal tissues)Oncogenic; metastasis driverChromatin remodeling, metastasis promotion[69]LINC02381Downregulated (tissues, MCF7, SKBR3)Tumor suppressorImmune-related; autophagy regulation[70, 81]LINC00511LINC01028UpregulationDownregulationOncogenic;Tumor SuppressorNME1 network; proliferation, survival, differentiation[75]LINC00961Downregulated (systems biology, case-control)Luminal correlatedsubtype detection[76]TUG1Downregulated (tissues)Tumor SuppressorReproductive factor; tumor characteristics[78]PNKYUpregulatedOncogenicProliferation, migration, EMT[79]GAS6-ASDownregulatedTumor suppressorPathobiology of cancer[82]lnc-MICAL3-2, LINC01063, lnc-DDX31, ENST0000615051, Lnc-TRIM43B-1Downregulated (tumors vs. control tissues)Tumor suppressorsDifferential expression; Lnc-TRIM43B-1 strongest biomarker[81]PLBD1-AS1, RAB11B-AS1, HERPUD2-AS1Upregulated (tumor vs. controls)OncogenicAutophagy-related lncRNA dysregulation[72]Abbreviations: ceRNA Competing Endogenous, LncRNA Long-non-coding RNA, EMT Epithelial-Mesenchymal Transition Table 2Major LncRNAs implicated in breast cancer (with Iranian evidence)lncRNAExpression in BCFunctional RoleMechanism/PathwayRef(s)DSCAM-AS1Upregulated (tumor tissues, adjacent tissues, blood)OncogenicPromotes cancer progression[55, 56]MALAT1Upregulated (tumor tissues, cell lines)Oncogenic; promotes proliferation & metastasisceRNA with miR-561-3p, ↑TOP2A[22, 48, 80]LncUSMycNUpregulatedOncogenicSupports proliferation, migration; knockdown induces apoptosis[59]SGO1-AS1Downregulated (tumors vs. adjacent tissues)Tumor suppressorMitotic regulation; loss may promote invasion/metastasis[61]ZEB2-AS1(ZEB2NAT)UpregulatedOncogenic; EMT regulatorTGF-β–induced; correlates with EMT markers[63–67]HOTAIRUpregulated (tumor vs. normal tissues)Oncogenic; metastasis driverChromatin remodeling, metastasis promotion[69]LINC02381Downregulated (tissues, MCF7, SKBR3)Tumor suppressorImmune-related; autophagy regulation[70, 81]LINC00511LINC01028UpregulationDownregulationOncogenic;Tumor SuppressorNME1 network; proliferation, survival, differentiation[75]LINC00961Downregulated (systems biology, case-control)Luminal correlatedsubtype detection[76]TUG1Downregulated (tissues)Tumor SuppressorReproductive factor; tumor characteristics[78]PNKYUpregulatedOncogenicProliferation, migration, EMT[79]GAS6-ASDownregulatedTumor suppressorPathobiology of cancer[82]lnc-MICAL3-2, LINC01063, lnc-DDX31, ENST0000615051, Lnc-TRIM43B-1Downregulated (tumors vs. control tissues)Tumor suppressorsDifferential expression; Lnc-TRIM43B-1 strongest biomarker[81]PLBD1-AS1, RAB11B-AS1, HERPUD2-AS1Upregulated (tumor vs. controls)OncogenicAutophagy-related lncRNA dysregulation[72]Abbreviations: ceRNA Competing Endogenous, LncRNA Long-non-coding RNA, EMT Epithelial-Mesenchymal Transition Major LncRNAs implicated in breast cancer (with Iranian evidence) ZEB2-AS1 (ZEB2NAT) LINC00511 LINC01028 Upregulation Downregulation Oncogenic; Tumor Suppressor Abbreviations: ceRNA Competing Endogenous, LncRNA Long-non-coding RNA, EMT Epithelial-Mesenchymal Transition Circulating lncRNAs Several circulating lncRNAs have been implicated in breast cancer. A total of 14 studies that were conducted in Iran were identified, and all were included in the qualitative analysis. Significant upregulation has been observed for H19, SPRY4 intronic transcript 1 (SPRY4-IT1), X-inactive specific transcript (XIST), urothelial carcinoma-associated 1 (UCA1), AC026904.1, colon cancer–associated transcript 1 (CCAT1), colon cancer–associated transcript 2 (CCAT2), integrin subunit beta 2 antisense RNA (ITGB2-AS), and AK058003. In contrast, the expression of maternally expressed 3 (MEG3), neuroblastoma-associated transcript 1 (NBAT1), NF-κB-interacting lncRNA (NKILA), growth arrest–specific transcript 5 (GAS5), EPB41L4A antisense RNA 2 (EPB41L4A-AS2), Z38, and BC040587 is reduced in breast cancer patients compared with healthy individuals [81]. Interestingly, SPRY4-IT1, XIST, and H19 have also been reported to be downregulated in certain contexts, suggesting cancer type- and stage-specific regulation. Conversely, CCAT1 was significantly downregulated in tumor tissues relative to normal breast tissue [83]. Furthermore, CRISPR/Cas9 analysis data showed that UCA1 depletion is a very effective method of regulating cellular proliferation in vitro in the breast cancer cell lines [84]. A review revealed that UCA1 and HCP5 lncRNAs are related to triple-negative breast cancer, suggesting that they could be selected as breast cancer biomarkers [85] Two additional circulating lncRNAs, AK058003 and AK094613 (MVIH), located on chromosome 10q22, were found to be upregulated in breast cancer patients compared with healthy controls [86]. Investigation on tumor tissues of Iranian patients, AK058003 and APOC1P1, were also significantly increased in tumor tissues compared to adjacent noncancerous tissues [87]. Rho GTPase-related lncRNAs Rho GTPase–associated lncRNAs have emerged as important regulators of cytoskeletal remodelling, invasion, and metastasis in breast cancer. Iranian studies on breast cancer cell lines revealed aberrant expression of these lncRNAs, directly impacting breast cancer progression [88]. Specifically, tissue analysis results showed that noncoding RNA activated by DNA damage (NORAD), NRAV lncRNAs, and RhoA mRNA were strongly increased in tumor tissues, with NRAV expression correlating with patient age, histological grade, and tubule formation [89]. CYTOR Circulating lncRNA CYTOR was found to be significantly upregulated in breast cancer patients compared with healthy controls. Its altered expression pattern supports its potential role as a non-invasive diagnostic biomarker for breast cancer [90]. LINC-ROR The long intergenic noncoding RNA–regulator of reprogramming (LINC-ROR) has been implicated in stem cell pluripotency and tumorigenesis [91]. In Iranian patients’ tissue analysis, LINC-ROR expression was significantly elevated in breast cancer tissues compared with adjacent noncancerous tissues, supporting its oncogenic role [73]. MRPS30-DT Breast cancer-associated transcript 54 (BRCAT54), also known as mitochondrial ribosomal protein 30 divergent transcript (MRPS30-DT), is an antisense lncRNA linked to mitochondrial ribosome regulation. Iranian studies on breast cancer tissue and cell lines demonstrated that both MRPS30-DT and its associated protein-coding gene, MRPS30, were significantly upregulated in breast cancer tissues and cell lines. In vitro, MRPS30-DT was highly expressed in MDA-MB-231 cells compared with normal fibroblasts [92]. LINC01405 LINC01405 acts as a competing endogenous RNA, sponging miR-19b and miR-497. In breast cancer cell lines, LINC01405 was upregulated in MDA-MB-231 cells but downregulated in SKBR3 and MCF7 cells. Its upregulation enhanced proliferation by promoting the expression of oncogenic targets such as AKT1, AKT3, mTOR, WNT3A, SMAD3, CYCLIN D1/D2, BCL2, and GSK3B [93]. LINC00475 In contrast, LINC00475 was significantly downregulated in breast tumor tissues compared to normal samples. Its expression positively correlated with FOXO1, suggesting a tumor-suppressive function in the Iranian breast cancer population [94]. SNHG LncRNAs Expression of mTOR and SNHG1, SNHG3, and SNHG5 lncRNAs was significantly elevated in breast cancer tissues compared with non-malignant tissues, and combined transcript levels could distinguish malignant from non-malignant tissues with 69% diagnostic accuracy, highlighting the potential role of SNHGs in breast cancer pathogenesis and as diagnostic biomarkers [95]. SNHG15, HCP5, and LINC01433 The lncRNAs SNHG15, HCP5, and LINC01433, along with the Hippo pathway regulators YAP and WWTR1, were found to be upregulated in breast tumors compared to normal tissues. Computational and experimental analyses confirmed their association with breast cancer progression [96]. Furthermore, WWTR1-AS1 was significantly overexpressed in tumor tissues relative to adjacent nontumor tissues [97]. Conversely, B4GALT1-AS1 was downregulated in breast tumors, with The Cancer Genome Atlas (TCGA) analysis revealing its correlation with YAP expression [76]. Another Hippo pathway–related lncRNA, LCAL4, was significantly upregulated in breast tumor tissues compared with controls, and its expression varied across subgroups and clinical stages [98]. Table 3 presents a summary of circulating and pathway-related lncRNAs in breast cancer. Table 3Summary of Circulating and pathway-related LncRNAs in breast cancerlncRNAExpression in BCProposed RoleRef (s)H19Upregulated/context-dependentBiomarker: variable expression across studies[83]SPRY4-IT1Upregulated/context-dependentBiomarker; variable expression[83]XISTUpregulated/context-dependentBiomarker; variable expression[83]UCA1UpregulatedCirculating biomarker, especially TNBC[83, 85]AC026904.1UpregulatedPotential biomarker[83]CCAT1Dysregulation (tumor vs. normal tissue)Circulating Biomarker[83, 84]CCAT2UpregulatedOncogenic role[83]ITGB2-ASUpregulatedOncogenic role[83]AK058003UpregulatedOncogenic biomarker[83, 87, 88]MEG3DownregulatedTumor suppressor[83]NBAT1DownregulatedTumor suppressor[83]NKILADownregulatedTumor suppressor[83]GAS5DownregulatedTumor suppressor[83]EPB41L4A-AS2DownregulatedTumor suppressor[83]Z38DownregulatedTumor suppressor[83]BC040587DownregulatedTumor suppressor[83]AK094613 (MVIH)UpregulatedOncogenic biomarker[87]APOC1P1UpregulatedOncogenic biomarker (Iranian validation)[88]NORADUpregulatedOncogenic; cytoskeletal regulation (Iran)[90]NRAVUpregulatedOncogenic; correlates with grade and age (Iran)[90]LINC-RORUpregulatedOncogenic; pluripotency regulator (Iran)[74]MRPS30-DTUpregulatedOncogenic; mitochondrial ribosome regulator (Iran)[93]LINC01405UpregulatedOncogenic; sponges miRNAs to promote proliferation[94]LINC00475DownregulatedTumor suppressor; correlated with FOXO1[95]SNHG1SNHG3SNHG5UpregulatedUpregulatedUpregulatedOncogenic; mTOR signaling pathway[96]SNHG15UpregulatedOncogenic; Hippo pathway[97]HCP5UpregulatedOncogenic; Hippo pathway[97]LINC01433UpregulatedOncogenic; Hippo pathway[97]WWTR1-AS1UpregulatedOncogenic; Hippo pathway[98]B4GALT1-AS1DownregulatedTumor suppressor (Hippo pathway-linked)[99]CYTORUpregulationOncogenic[91]Abbreviations: Triple-Negative Breast Cancer (TNBC) Table 3Summary of Circulating and pathway-related LncRNAs in breast cancerlncRNAExpression in BCProposed RoleRef (s)H19Upregulated/context-dependentBiomarker: variable expression across studies[83]SPRY4-IT1Upregulated/context-dependentBiomarker; variable expression[83]XISTUpregulated/context-dependentBiomarker; variable expression[83]UCA1UpregulatedCirculating biomarker, especially TNBC[83, 85]AC026904.1UpregulatedPotential biomarker[83]CCAT1Dysregulation (tumor vs. normal tissue)Circulating Biomarker[83, 84]CCAT2UpregulatedOncogenic role[83]ITGB2-ASUpregulatedOncogenic role[83]AK058003UpregulatedOncogenic biomarker[83, 87, 88]MEG3DownregulatedTumor suppressor[83]NBAT1DownregulatedTumor suppressor[83]NKILADownregulatedTumor suppressor[83]GAS5DownregulatedTumor suppressor[83]EPB41L4A-AS2DownregulatedTumor suppressor[83]Z38DownregulatedTumor suppressor[83]BC040587DownregulatedTumor suppressor[83]AK094613 (MVIH)UpregulatedOncogenic biomarker[87]APOC1P1UpregulatedOncogenic biomarker (Iranian validation)[88]NORADUpregulatedOncogenic; cytoskeletal regulation (Iran)[90]NRAVUpregulatedOncogenic; correlates with grade and age (Iran)[90]LINC-RORUpregulatedOncogenic; pluripotency regulator (Iran)[74]MRPS30-DTUpregulatedOncogenic; mitochondrial ribosome regulator (Iran)[93]LINC01405UpregulatedOncogenic; sponges miRNAs to promote proliferation[94]LINC00475DownregulatedTumor suppressor; correlated with FOXO1[95]SNHG1SNHG3SNHG5UpregulatedUpregulatedUpregulatedOncogenic; mTOR signaling pathway[96]SNHG15UpregulatedOncogenic; Hippo pathway[97]HCP5UpregulatedOncogenic; Hippo pathway[97]LINC01433UpregulatedOncogenic; Hippo pathway[97]WWTR1-AS1UpregulatedOncogenic; Hippo pathway[98]B4GALT1-AS1DownregulatedTumor suppressor (Hippo pathway-linked)[99]CYTORUpregulationOncogenic[91]Abbreviations: Triple-Negative Breast Cancer (TNBC) Summary of Circulating and pathway-related LncRNAs in breast cancer SNHG1 SNHG3 SNHG5 Upregulated Upregulated Upregulated Abbreviations: Triple-Negative Breast Cancer (TNBC) CircRNAs Circular RNAs (circRNAs) are a type of noncoding RNA that has a covalently closed loop structure formed by backsplicing of a pre-mRNA molecule. Unlike linear RNAs, circRNAs lack both 5’ caps and 3’ poly (A) tails, and their circular structure confers potential for the regulation of gene expression through interactions with RNA-binding proteins and microRNAs. CircRNAs have been implicated in a variety of diseases, such as cancer [99]. Overall, eight circRNA-related studies were identified, and four were included after applying our keyword-based criteria. The results of an in silico analysis revealed a panel of hub circRNAs that play important roles in breast cancer progression. These molecules are considered breast cancer therapeutic targets and include hsa-circ-0003227, hsa-circ-0001955, hsa-circ-0020080, hsa-circ-0001666, and hsa-circ-0065173 [100]. Hsa-circ-0005046 and hsa-circ-0001791 act as oncogenes in the PI3K/AKT pathway in breast cancer. These noncoding RNAs have been recommended as diagnostic hallmarks of breast cancer [101]. Findings identified biomarkers for the discrimination of breast cancer subtypes. The results of this in silico and in vitro data analysis revealed the significant upregulation of hsa-circ-0044234 and the connection between its expression and the miR-135b-5p/GATA3 CeRNA axis in triple-negative breast cancer [102]. Circ-0087558 An in silico study demonstrated the potential role of Circ-0087558 as a member of endogenous networks in developing breast cancer metastasis to the brain. Five protein-coding genes of PHLDA1, SLC12A2, MMP2, RGP1, and MAP2K6 were significantly upregulated in brain metastatic tissues compared to primary breast cancer. Moreover, circ_0087558/miR-604/MMP2 and MMP2/miR-1248/Circ-0087558/miR-643/MAP2K6 networks are involved in the metastasis of breast tumors to the brain [103]. Circ_0000977 Circ_0000977 is downregulated in TNBC in both tumor tissues and blood samples compared to non-TNBC cases, showing promise as a circulating biomarker while also regulating the miR-135b-5p/APC-GATA3 axis, suggesting both diagnostic and mechanistic roles [104]. Circ‐FAF1 & circ‐ELP Serum circ-FAF1 and circ‐ELP3 have been proposed as novel circulating biomarkers with diagnostic potential for breast cancer [105]. The circRNA-associated genetic markers from the above studies are listed in Table 4.Table 4Studies in relation to circRNA gene markers among the Iranian breast cancer patientsCircRNAExpression in BCProposed RoleRef (s)Hsa_circ_0005046UpregulationOncogene; PI3K/AKT pathway[103]Hsa_circ_0001791UpregulationOncogene; PI3K/AKT pathway[103]Hsa_circ_0044234UpregulationOncogenic; TNBC progression[104]Hsa_circ_0000977DownregulationTumor Suppressor; TNBC; ceRNA regulatory network[106]Circ-FAF1Circ-ELP3Upregulation;UpregulationOncogenic; Diagnostic value[107]Abbreviations:Triple-Negative Breast Cancer (TNBC); Competing Endogenous RNA (CeRNA); Circle RNA (CircRNA) Table 4Studies in relation to circRNA gene markers among the Iranian breast cancer patientsCircRNAExpression in BCProposed RoleRef (s)Hsa_circ_0005046UpregulationOncogene; PI3K/AKT pathway[103]Hsa_circ_0001791UpregulationOncogene; PI3K/AKT pathway[103]Hsa_circ_0044234UpregulationOncogenic; TNBC progression[104]Hsa_circ_0000977DownregulationTumor Suppressor; TNBC; ceRNA regulatory network[106]Circ-FAF1Circ-ELP3Upregulation;UpregulationOncogenic; Diagnostic value[107]Abbreviations:Triple-Negative Breast Cancer (TNBC); Competing Endogenous RNA (CeRNA); Circle RNA (CircRNA) Studies in relation to circRNA gene markers among the Iranian breast cancer patients Circ-FAF1 Circ-ELP3 Upregulation; Upregulation Abbreviations:Triple-Negative Breast Cancer (TNBC); Competing Endogenous RNA (CeRNA); Circle RNA (CircRNA) DNA methylation DNA methylation is a key epigenetic modification that regulates gene expression and plays a central role in cancer development [106]. A total of 12 studies on DNA methylation, including those conducted in Iran, were identified, of which 4 met the inclusion criteria and were included in the qualitative analysis. The progesterone receptor (PGR) gene is strongly associated with breast cancer risk [107]. An Iranian study demonstrated a significant inverse association between promoter hypermethylation of PGR and breast cancer susceptibility in reproductive compared with non-reproductive women [108]. The CXX1 gene (also known as FAM127A), located on the X chromosome [109], has shown altered methylation patterns in several cancers, including gastric cancer [110]. For the first time, Iranian researchers reported hypermethylation of CpG islands in the CXX1 promoter in breast cancer patients. This was significantly associated with reduced gene expression compared with healthy controls, suggesting a diagnostic potential for breast cancer detection in this population [111]. The ISL1 gene, which encodes an insulin gene enhancer protein critical for embryonic development [111], and MGMT (O-6-methylguanine-DNA methyltransferase), a DNA repair gene [112], have also been studied as potential methylation markers. In Iranian women with breast cancer, tumor tissues displayed significantly higher promoter hypermethylation of ISL1 and MGMT than normal tissues, accompanied by reduced expression levels of both genes [112]. Notably, decreased ISL1 expression correlated with histological grade and HER2/ER status, while reduced MGMT expression was associated with larger tumor size. These findings suggest that the hypermethylation of ISL1 and MGMT may serve as diagnostic and prognostic biomarkers for breast cancer. In another study, the retinoic acid receptor-beta 2 (RARβ2) promoter hypermethylation in blood and tumor tissues was significantly associated with breast cancer susceptibility, with a higher frequency in tumors than adjacent normal tissues; evidence across populations consistently supports its role as a risk marker [113]. ESR1 rs2234693 An Iranian study indicated that ESR1 gene polymorphism (rs2234693), promoter methylation status, and serum heavy metal levels could serve as potential biomarkers for breast cancer diagnosis. Table 5 contains DNA methylation markers in breast cancer from Iranian studies [114].Table 5DNA methylation markers in breast cancer (Iranian studies)GeneFunctionMethylation EffectClinical Association (Iranian Population)Ref (s)PGRProgesterone receptor; regulates hormone signalingPromoter hypermethylation reduced expressionInverse correlation with breast cancer susceptibility in reproductive vs. non-reproductive women[110]CXX1 (FAM127A)X-linked gene; role in cell regulationPromoter hypermethylation reduced expressionHypermethylation is associated with downregulation of expression in breast cancer tissues vs. controls[113]ISL1Insulin gene enhancer protein; embryonic developmentPromoter hypermethylation reduced expressionDownregulation correlated with histological grade, HER2, and ER status[114]MGMTDNA repair protein (O-6-methylguanine-DNA methyltransferase)Promoter hypermethylation reduced expressionReduced expression associated with tumor size; proposed diagnostic and prognostic marker[114]RARβ2DNA methylationPromoter hypermethylationMethylation; breast cancer progression[115]Abbreviations: ER status Estrogen Receptor status, HER2 Human Epidermal Growth Factor Receptor 2 Table 5DNA methylation markers in breast cancer (Iranian studies)GeneFunctionMethylation EffectClinical Association (Iranian Population)Ref (s)PGRProgesterone receptor; regulates hormone signalingPromoter hypermethylation reduced expressionInverse correlation with breast cancer susceptibility in reproductive vs. non-reproductive women[110]CXX1 (FAM127A)X-linked gene; role in cell regulationPromoter hypermethylation reduced expressionHypermethylation is associated with downregulation of expression in breast cancer tissues vs. controls[113]ISL1Insulin gene enhancer protein; embryonic developmentPromoter hypermethylation reduced expressionDownregulation correlated with histological grade, HER2, and ER status[114]MGMTDNA repair protein (O-6-methylguanine-DNA methyltransferase)Promoter hypermethylation reduced expressionReduced expression associated with tumor size; proposed diagnostic and prognostic marker[114]RARβ2DNA methylationPromoter hypermethylationMethylation; breast cancer progression[115]Abbreviations: ER status Estrogen Receptor status, HER2 Human Epidermal Growth Factor Receptor 2 DNA methylation markers in breast cancer (Iranian studies) Abbreviations: ER status Estrogen Receptor status, HER2 Human Epidermal Growth Factor Receptor 2 Discussion This systematic review summarizes epigenetic alterations in breast cancer within the Iranian population, highlighting long non-coding RNAs (lncRNAs), microRNAs (miRNAs), circular RNAs (circRNAs), and DNA methylation as key regulators of tumor biology. Oncogenic miRNAs (miR-21, miR-155) and lncRNAs (MALAT1, ZEB2-AS1, HOTAIR, LINC-ROR) drive proliferation and metastasis, whereas tumor suppressor miRNAs (miR-34a, miR-200c) and lncRNAs (LINC00475, LINC02381, MEG3, GAS5) are frequently downregulated. Circulating lncRNAs such as AK058003, UCA1, and CCAT1 show potential as non-invasive biomarkers, and DNA methylation silences tumor suppressor genes, including PGR, ISL1, MGMT, and CXX1. Specific dietary and lifestyle factors in the Iranian population may contribute to distinct DNA methylation patterns, potentially influencing the methylation frequency of genes such as PGR. Further research is warranted to confirm these associations. Collectively, these findings underscore the central role of epigenetic mechanisms in breast cancer pathogenesis and their potential as biomarkers and therapeutic targets. Among Iranian breast cancer cohorts, ZEB2-AS1, MALAT1, AK058003, and DSCAM-AS1 are the most frequently studied lncRNAs, consistently implicated in critical oncogenic processes including cell proliferation, migration, invasion, and metastasis (Table 5). ZEB2-AS1 has been extensively studied for its regulatory role in the epithelial-to-mesenchymal transition (EMT), a crucial step in cancer metastasis [62]. Its upregulation has been associated with aggressive tumour behaviour and poor clinical outcomes, suggesting its potential as a prognostic marker. MALAT1, one of the most well-characterized lncRNAs globally [115, 116], has also been extensively studied in Iranian breast cancer cohorts. Its expression levels have been linked to tumor progression and metastasis, particularly in hormone receptor-positive subtypes [117]. MALAT1 is also known to interact with multiple signaling pathways, making it a promising target for therapeutic intervention. lncRNA AK058003 is overexpressed in breast cancer and promotes migration and invasion, particularly in ER-positive cell lines [87]. While its direct link to estrogen signaling remains unclear, its elevated levels in both tissues and cell lines suggest a role in hormone-responsive tumor growth and highlight its potential as a biomarker and therapeutic target [86, 118]; however, further research is needed to clarify its exact function. DSCAM-AS1 has gained prominence due to its estrogen receptor–related expression patterns. Its overexpression in breast cancer, particularly in ER-positive cases, indicates it may contribute to hormonal regulation of tumor growth. Iranian studies on cell lines have highlighted their potential as both a biomarker and a therapeutic target [119]. MicroRNAs have been a major focus of epigenetic research in Iranian breast cancer cohorts. Consistent dysregulation of miR-155, miR-9, miR-21, miR-29b, miR-34a, miR-92a-3p, miR-125a-5p, and miR-561-3p has been reported across multiple studies. Among these, miR-155 is the most frequently studied, consistently showing upregulation in tumor tissues and patient samples. Evidence from both Iranian and global studies highlights its role as a diagnostic and prognostic marker, linking it to tumor progression, metastasis, epithelial-to-mesenchymal transition (EMT), and poor survival [50, 120]. Its presence in blood and exosomes further supports its potential as a non-invasive biomarker. Moreover, therapeutic strategies targeting miR-155, such as antagomiRs, have demonstrated efficacy in preclinical models, reinforcing its potential as a universal biomarker and therapeutic target in breast cancer [51, 121, 122]. Moreover, our review identified rs2043556 in miR-605 as being associated with breast cancer progression. This finding, reported in two studies and meeting our inclusion criteria for biomarker selection, highlights miR-605 as a potential epigenetic regulator and underscores the need for further investigation in larger, diverse cohorts. Beyond well-characterized lncRNAs, Iranian studies have reported several novel transcripts, including lncUSMycN, SGO-AS1, PLBD1-AS1, RAB11B-AS1, and HERPUD2-AS1. Their biological roles in breast cancer remain largely unexplored in non-Iranian populations, suggesting they may serve as population-specific epigenetic markers influenced by unique genetic backgrounds or environmental exposures. Further functional studies are needed to elucidate their mechanisms and clinical relevance. Cross-population comparisons highlight two key observations: first, several markers, including ZEB2-AS1, MALAT1, AK058003, DSCAM-AS1, and miR-155, are consistently reported across different ethnic groups, supporting their role as universal biomarkers of breast cancer. Recent studies have further emphasized the pivotal regulatory roles of non-coding RNAs in breast cancer progression, therapeutic resistance, and tumor microenvironment modulation, reinforcing their potential as clinically actionable biomarkers [123]. Second, novel markers identified predominantly in Iranian patients offer opportunities to uncover region-specific molecular signatures and expand the repertoire of potential diagnostic tools. Despite these promising findings, several limitations remain. Most Iranian studies have been conducted on relatively small cohorts using heterogeneous methodologies and detection platforms. Additionally, many reported associations lack independent replication or external validation, limiting the strength and generalizability of the evidence. Addressing these gaps will require larger, multicentre studies, ideally integrating multi-omics approaches that combine transcriptomics, epigenomics, and proteomics. Functional studies are also essential to elucidate the molecular mechanisms of novel lncRNAs, while clinical trials will be critical to establish the diagnostic, prognostic, and therapeutic utility of these biomarkers in breast cancer management. Conclusion Epigenetic modifications, including noncoding RNAs (miRNAs, lncRNAs) and DNA methylation, play central roles in breast cancer initiation, progression, and metastasis. Iranian studies highlight both population-specific alterations, such as aberrant expression of MALAT1, HOTAIR, ZEB2-AS1, and key miRNAs (miR-155 and miR-605), and promoter hypermethylation of genes like ISL1, MGMT, and CXX1, consistent with global findings. These markers show promise as diagnostic, prognostic, and therapeutic tools, with potential for non-invasive detection. Future research with larger cohorts, multi-omics integration, and functional validation is needed to translate these insights into clinical applications, paving the way for personalized therapy and improved outcomes (Fig. 3). Prospective clinical studies are encouraged to validate the identified biomarkers and assess their diagnostic and prognostic utility in diverse populations. Fig. 3Conceptual pathway of epigenetic modifiers in breast cancer. The chart summarizes how key epigenetic regulators (n = 269 studies), including microRNAs (n = 33 studies from 37 studies), long noncoding RNAs (n = 20 from 117 studies), circulating RNAs (n = 14 studies), circRNAs (n = 8 studies) and DNA methylation (n = 4 from 12 studies), alter gene expression patterns involved in tumor initiation, progression, invasion, and metastasis. Upregulated (red) oncogenic regulators, downregulated (blue) tumor-suppressive elements, and hypermethylated (green) components converge to disrupt normal cellular signaling, highlighting their potential as diagnostic biomarkers and therapeutic targets. All the abbreviations were included in the list of abbreviations Conceptual pathway of epigenetic modifiers in breast cancer. The chart summarizes how key epigenetic regulators (n = 269 studies), including microRNAs (n = 33 studies from 37 studies), long noncoding RNAs (n = 20 from 117 studies), circulating RNAs (n = 14 studies), circRNAs (n = 8 studies) and DNA methylation (n = 4 from 12 studies), alter gene expression patterns involved in tumor initiation, progression, invasion, and metastasis. Upregulated (red) oncogenic regulators, downregulated (blue) tumor-suppressive elements, and hypermethylated (green) components converge to disrupt normal cellular signaling, highlighting their potential as diagnostic biomarkers and therapeutic targets. All the abbreviations were included in the list of abbreviations Supplementary Information Supplementary Material 1. Supplementary Material 1.